Trial Profile

A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 May 2025 According to a CG Oncolgy media release, enrollment completion from this study is expected in the second half of 2025 .
31 Mar 2025 According to a CG Oncolgy media release, data from the study will be presented as a late breaker as part of American Urological Association (AUA)'s Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s). The AUA Annual Meeting, scheduled from April 26-29, 2025, in Las Vegas, Nevada
12 Mar 2025 According to a CG Oncolgy media release, company data from this study will be presented at the 40th Annual European Association of Urology (EAU) Congress taking place in Green Area Retiro, Ifema, Madrid, on March 21, 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com